Sabra Health Care REIT, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Sabra Health Care REIT, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	261	408	623	662	599	570	625	648	703	775
General and administrative	17.7	32.4	37.1	30.9	32.8	34.7	39.6	47.5	50.1	53.7
Interest expense	64.9	88.4	147	127	100	98.6	105	113	115	112
Other non-operating income	4	52	130	-11.9	4.48	-21.9	-13.5	-75.6	4.83	9.36
Pre-tax income	71.3	159	288	79.2	156	80.7	21.7	18.7	128	153
Income tax	1.05	0.65	3.01	3.4	0.71	1.85	1.24	2	1.01	1.84
Net income to minority interests	-0.07	-0.02	0.03	0.02	0	0		0	0	-0.1
Net income	70.3	158	279	69	138	-113	-77.6	13.8	127	156
EPS, basic	0.92	1.40	1.51	0.37	0.67	-0.52	-0.34	0.06	0.54	0.64
EPS, diluted	0.92	1.40	1.51	0.37	0.67	-0.52	-0.34	0.06	0.54	0.64
Shares, basic (weighted)	65.3	106	178	187	206	219	231	231	233	241
Shares, diluted (weighted)	65.5	106	179	188	207	219	231	233	236	244
Dividend per share	1.67	1.73	1.80	1.80	1.35	1.20	1.20	1.20	1.20	1.20

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	25.7	519	50.2	39.1	59.1	112	49.3	41.3	60.5	71.5
Lease right-of-use assets				9.3			8.5	11.6	7	6.5
Intangible assets	26.3	167	131	102	82.8	54.1	40.1	30.9	27.5	65.3
Total assets	2,266	7,032	6,665	6,069	5,986	5,967	5,748	5,386	5,304	5,493
Total liabilities	1,250	3,595	3,411	2,581	2,576	2,587	2,691	2,584	2,562	2,670
Total debt	1,211	3,394	3,232	2,402	2,372	2,394	2,507	2,414	2,418	2,529
Paid-in capital	1,209	3,637	3,508	4,072	4,163	4,482	4,487	4,495	4,593	4,836
Other comprehensive income	-1.8	11.3	12.3	-12.4	-39.9	-10	19.1	23.7	20.9	-3.57
Shareholders' equity	1,016	3,433	3,250	3,488	3,409	3,380	3,056	2,803	2,741	2,822
Minority interests	0.04	4.44	4.33	0					0	1.95
Total equity	1,016	3,437	3,255	3,488	3,409	3,380	3,056	2,803	2,741	2,824
Total liabilities and equity	2,266	7,032	6,665	6,069	5,986	5,967	5,748	5,386	5,304	5,493
Shares outstanding	65.3	178	178	205	211	230	231	231	238	252

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	70.3	158	279	69	138	-113	-77.6	13.8	127	156
Depreciation and amortization	68.5	114	191	182	177	179	188	183	170	187
Stock-based compensation	7.5	8.36	7.65	9.82	7.91	7.91	7.45	7.92	8.99	11.4
Change in payables	7.31	-71.2	-11.7	-13.9	3.66	14.5	-13.3	8.34	-7.09	1.6
Cash from operations	176	136	361	372	355	356	316	301	311	349
Purchases of investments	-7.35	-2.75	-5.31	0
Cash from investing	142	-183	-258	263	-136	-336	-216	103	-109	-378
Stock issued	-1.29	367
Dividends paid	-119	-182	-325	-335	-278	-263	-277	-277	-280	-289
Cash from financing	-301	599	-629	-646	-202	30.1	-162	-410	-182	40.8
Exchange rate effect	0.03	0.74	-0.54	0.35	0.09	0.03	0.27	-0.61	-0.36	0.39
Net change in cash	17.4	552	-527	-10.9	16.3	50.3	-62.2	-6.6	20	11.4
Interest paid	59.2	69.7	138	124	92.6	85.5	97.7	102	105	111
Income taxes paid	0.85	0.71	1.8	3.91	2.44	1.84	1.66	1.67	1.39	1.5

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $19.85 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Pre-tax margin	7.0%	Pre-tax income / revenue.
Net margin	7.6%	Net income / revenue.
Operating cash flow margin	43.2%	Cash from operations / revenue.
Effective tax rate	3.5%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	2.4%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	1.2%	Net income / average total assets.
Stock-based pay / revenue	1.5%	Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue	24.4%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	10.2%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	7.4%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	5.3%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	22.8%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 5y	2.4%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	18.5%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 5y	-0.9%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	12.3%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	3.4%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-0.4%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Dividend per share growth, 1y	0.0%	Dividend per share vs the same period a year earlier. Only from a positive base.
Dividend per share CAGR, 3y	0.0%	Compound annual growth of dividend per share over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Dividend per share CAGR, 5y	-2.3%	Compound annual growth of dividend per share over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	2.9%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-2.6%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-3.7%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	3.6%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-1.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-1.7%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	3.6%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	1.9%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	3.4%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Debt / equity	0.95x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	47.6%	Total debt / total assets.
Liabilities / assets	50.1%	Total liabilities / total assets.
Net debt	$2.39B	Total debt - cash - short-term investments. Negative means more cash than debt.
Goodwill and intangibles / assets	1.5%	(Goodwill + intangible assets) / total assets.
Tangible book value	$2.67B	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.16x	Revenue / average total assets.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.26	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$3.41	Revenue / diluted weighted shares.
Operating cash flow per share	$1.47	Cash from operations / diluted weighted shares.
Book value per share	$10.77	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$10.44	Tangible book value / shares outstanding.
Cash per share	$0.91	(Cash + short-term investments) / shares outstanding.
Payout ratio	455.5%	Dividends paid / net income, when net income is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$5.07B	Share price x shares outstanding.
Enterprise value	$7.47B	Market cap + total debt - cash - short-term investments.
P/E	77.5x	Market cap / net income. Only when net income is positive.
P/S	5.90x	Market cap / revenue.
P/B	1.84x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	1.90x	Market cap / tangible book value, when positive.
P/OCF	13.6x	Market cap / cash from operations, when positive.
EV/Sales	8.69x	Enterprise value / revenue.
Earnings yield	1.3%	Net income / market cap (the inverse of P/E).
Dividend yield	5.9%	Dividends paid over the period / market cap.
Shareholder yield	5.9%	(Dividends paid + share buybacks) / market cap.

What was Sabra Health Care REIT, Inc.'s revenue in fiscal 2025?

Sabra Health Care REIT, Inc. reported revenue of $774.6M for fiscal 2025, 10.2% higher than the year before.

Was Sabra Health Care REIT, Inc. profitable in fiscal 2025?

Yes. Net income was $155.6M, a net margin of 20.1%.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Sabra Health Care REIT, Inc.